Silo Pharma Inc. (SILO) Emerging Leader as Psyched
Post# of 137
(Total Views: 442)
Posted On: 04/11/2022 3:40:06 PM
Silo Pharma Inc. (SILO) Emerging Leader as Psychedelics ‘on the Cusp of Entering Mainstream Psychiatry’
- Mainstream acceptance of psychedelics took a “significant leap forward” with study results published in “Nature Medicine”
- Many say it is only a matter of time before FDA grants approval for psychoactive compounds to be used therapeutically
- SILO is focused on merging traditional therapeutics with psychedelic research for people suffering from underserved indications
“The Psychedelic Revolution Is Coming,” proclaims a “New York Times” article, which notes that as a result, psychiatry may never be the same. This isn’t news for companies such as Silo Pharma (OTCQB: SILO). A developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, Silo has long been familiar with the potential of psychedelics.
“It’s been a long, strange trip in the four decades since Rick Doblin, a pioneering psychedelics researcher, dropped his first hit of acid in college and decided to dedicate his life to the healing powers of mind-altering compounds,” reported the Times, noting that psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. “Even as antidrug campaigns led to the criminalization of Ecstasy, LSD and magic mushrooms, and drove most researchers from the field, Dr. Doblin continued his quixotic crusade with financial help from his parents.
“Dr. Doblin’s quest to win mainstream acceptance of psychedelics took a significant leap forward on Monday when the journal ‘Nature Medicine’ published the results of his lab’s study on MDMA, the club drug popularly known as Ecstasy and Molly,” the article continued. “The study, the first phase 3 clinical trial conducted with psychedelic-assisted therapy, found that MDMA paired with counseling brought marked relief to patients with severe post-traumatic stress disorder.”
The article observed that only a few weeks ago, the “New England Journal of Medicine” also published a study highlighting the benefits of treating depression with psilocybin, the psychoactive ingredient in magic mushrooms. These studies “have excited scientists, psychotherapists and entrepreneurs in the rapidly expanding field of psychedelic medicine. They say it is only a matter of time before the Food and Drug Administration grants approval for psychoactive compounds to be used therapeutically — for MDMA as soon as 2023, followed by psilocybin a year or two later. After decades of demonization and criminalization, psychedelic drugs are on the cusp of entering mainstream psychiatry, with profound implications for a field that in recent decades has seen few pharmacological advancements for the treatment of mental disorders and addiction. The need for new therapeutics has gained greater urgency amid a national epidemic of opioid abuse and suicides.”
This urgency aligns with Silo Pharma’s mission identifying assets to license while funding transformative research for the well-being of patients and the healthcare industry. The company focuses specifically on patients suffering from largely underserved indications like post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders.
The company has filed four U.S. provisional patent applications and a pipeline including a research collaboration with Columbia University and UCSF; an investigator-led sponsored study with Maastricht University; an option agreement with the University of Maryland, Baltimore for patented homing peptides targeting rheumatoid arthritis; licensing for a patented novel peptide-guided drug-delivery approach for the treatment of multiple sclerosis; and upfront funding for a licensing deal for its psilocybin cancer therapeutic applications.
Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research that the company believes will be transformative to the well-being of patients and the healthcare industry.
For more information, visit the company’s website at www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://nnw.fm/SILO
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Mainstream acceptance of psychedelics took a “significant leap forward” with study results published in “Nature Medicine”
- Many say it is only a matter of time before FDA grants approval for psychoactive compounds to be used therapeutically
- SILO is focused on merging traditional therapeutics with psychedelic research for people suffering from underserved indications
“The Psychedelic Revolution Is Coming,” proclaims a “New York Times” article, which notes that as a result, psychiatry may never be the same. This isn’t news for companies such as Silo Pharma (OTCQB: SILO). A developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, Silo has long been familiar with the potential of psychedelics.
“It’s been a long, strange trip in the four decades since Rick Doblin, a pioneering psychedelics researcher, dropped his first hit of acid in college and decided to dedicate his life to the healing powers of mind-altering compounds,” reported the Times, noting that psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. “Even as antidrug campaigns led to the criminalization of Ecstasy, LSD and magic mushrooms, and drove most researchers from the field, Dr. Doblin continued his quixotic crusade with financial help from his parents.
“Dr. Doblin’s quest to win mainstream acceptance of psychedelics took a significant leap forward on Monday when the journal ‘Nature Medicine’ published the results of his lab’s study on MDMA, the club drug popularly known as Ecstasy and Molly,” the article continued. “The study, the first phase 3 clinical trial conducted with psychedelic-assisted therapy, found that MDMA paired with counseling brought marked relief to patients with severe post-traumatic stress disorder.”
The article observed that only a few weeks ago, the “New England Journal of Medicine” also published a study highlighting the benefits of treating depression with psilocybin, the psychoactive ingredient in magic mushrooms. These studies “have excited scientists, psychotherapists and entrepreneurs in the rapidly expanding field of psychedelic medicine. They say it is only a matter of time before the Food and Drug Administration grants approval for psychoactive compounds to be used therapeutically — for MDMA as soon as 2023, followed by psilocybin a year or two later. After decades of demonization and criminalization, psychedelic drugs are on the cusp of entering mainstream psychiatry, with profound implications for a field that in recent decades has seen few pharmacological advancements for the treatment of mental disorders and addiction. The need for new therapeutics has gained greater urgency amid a national epidemic of opioid abuse and suicides.”
This urgency aligns with Silo Pharma’s mission identifying assets to license while funding transformative research for the well-being of patients and the healthcare industry. The company focuses specifically on patients suffering from largely underserved indications like post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders.
The company has filed four U.S. provisional patent applications and a pipeline including a research collaboration with Columbia University and UCSF; an investigator-led sponsored study with Maastricht University; an option agreement with the University of Maryland, Baltimore for patented homing peptides targeting rheumatoid arthritis; licensing for a patented novel peptide-guided drug-delivery approach for the treatment of multiple sclerosis; and upfront funding for a licensing deal for its psilocybin cancer therapeutic applications.
Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research that the company believes will be transformative to the well-being of patients and the healthcare industry.
For more information, visit the company’s website at www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://nnw.fm/SILO
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)SILO Pharma Inc. (SILO) Stock Research Links
Scroll down for more posts ▼